You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: ACE inhibitors, but not angiotensin II receptor antagonists, reduce all cause mortality in diabetic nephropathy

https://doi.org/10.1136/ebm.10.3.77

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329:828.
    OpenUrlAbstract/FREE Full Text

    
 
 Q In patients with diabetic nephropathy, what are the effects of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor antagonists (AIIRAs)?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Nephrology ★★★★★☆☆ Endocrine ★★★★★★☆

    METHODS

    Embedded ImageData sources:

    Medline (1966 to September 2003), EMBASE/Excerpta Medica (1988 to September 2003), the Cochrane Library, conference proceedings, and contact with experts.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) in any language of ⩾6 months’ duration comparing ACE inhibitors or AIIRAs with placebo, no treatment, or each other in patients with any stage of diabetic nephropathy. Studies were assessed for methodological quality.

    Embedded ImageOutcomes:

    all cause mortality …

    View Full Text

    Footnotes

    • For correspondence: Dr G F Strippoli, University of Sydney, New South Wales, Australia. gfmstrippolialiceposta.it

    • Sources of funding: Australia-Europe Scholarship; NHMRC Centre for Clinical Research Excellence Grant; Italian Society of Nephrology.